http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019117632-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f3a218a73266e3df2aacace1fefbbda |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate | 2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f6f8e50d21fe738696c09e37cd2e0cd |
| publicationDate | 2019-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019117632-A1 |
| titleOfInvention | Methods of treating developmental disorders with gaboxadol |
| abstract | Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020247127-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11123332-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4051272-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11597726-B2 |
| priorityDate | 2015-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 206.